Den europeiske union - spansk - EMA (European Medicines Agency)

roche registration ltd. - daclizumab - graft rejection; kidney transplantation - inmunosupresores - zenapax está indicado para la profilaxis del rechazo agudo de órganos en de novo trasplante renal alógeno y debe ser utilizado concomitantemente con un régimen inmunosupresor, como ciclosporina y corticosteroides en pacientes que no son altamente inmunizados.

Den europeiske union - spansk - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - otros agentes antineoplásicos - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Den europeiske union - spansk - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinoma, célula escamosa - agentes antineoplásicos - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Den europeiske union - spansk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

instituto grifols s.a. - inmunoglobulina humana normal - soluciÓn inyectable - 200 mg/ml inyectable 50 ml - inmunoglobulina humana normal 200 mg - inmunoglobulinas humanas normales para adm. extravascular

Chile - spansk - ISPC (Instituto de Salud Pública de Chile)

advance scientific de chile s.p.a. - tiotepa - tiotepa 100,00 mg - tiotepa está indicado, en combinación con otros medicamentos quimioterápicos: • con o sin radiación corporal total (rct), como tratamiento de acondicionamiento antes de un trasplante de células madre hematopoyéticas (tcmh) alogénico o autólogo en pacientes adultos y pediátricos con enfermedades hematológicas; • cuando la quimioterapia en dosis altas con soporte de tcmh está indicada para el tratamiento de tumores sólidos en pacientes adultos y pediátricos

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

alk-abello a/s - extracto alergenico de dermatophagoides pteronyssinus; extracto alergenico de dermatophagoides farinae - liofilizado sublingual - 12 sq-hdm - extracto alergenico de dermatophagoides pteronyssinus 6 sq-hdm; extracto alergenico de dermatophagoides farinae 6 sq-hdm - Ácaros de polvo ambiental

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

stallergenes - extracto alergenico de dermatophagoides pteronyssinus; extracto alergenico de dermatophagoides pteronyssinus; extracto alergenico de dermatophagoides farinae; extracto alergenico de dermatophagoides farinae - comprimido sublingual - 100 ir + 300 ir - extracto alergenico de dermatophagoides pteronyssinus 50 ir; extracto alergenico de dermatophagoides pteronyssinus 150 ir; extracto alergenico de dermatophagoides farinae 150 ir; extracto alergenico de dermatophagoides farinae 50 ir - Ácaros de polvo ambiental

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

stallergenes - extracto alergenico de dermatophagoides pteronyssinus; extracto alergenico de dermatophagoides farinae - comprimido sublingual - 300 ir - extracto alergenico de dermatophagoides pteronyssinus 150 ir; extracto alergenico de dermatophagoides farinae 150 ir - Ácaros de polvo ambiental

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

italfarmaco s.a. - lenograstim - polvo y disolvente para soluciÓn inyectable - 13 millones ui - lenograstim 13 millones ui - lenograstim